Journal ArticleOPEN ACCESS

Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib

  • Motzer R
  • Hutson T
  • McCann L
  • et al.
New England Journal of Medicine (2014) 370(18) 1769-1770
DOI: 10.1056/nejmc1400731
249Citations
Citations of this article
159Readers
Mendeley users who have this article in their library.

Abstract

Survival results are now mature for a noninferiority trial comparing pazopanib with sunitinib in renal-cell carcinoma. Median survival was 42.5 months with pazopanib and 43.6 months with sunitinib, a difference that wasnot significant.

Cite

CITATION STYLE

APA

Motzer, R. J., Hutson, T. E., McCann, L., Deen, K., & Choueiri, T. K. (2014). Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. New England Journal of Medicine, 370(18), 1769–1770. https://doi.org/10.1056/nejmc1400731

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free